No Data
No Data
Aura Biosciences: A Strong Buy on Promising Cancer Treatments and Solid Financials
Aura Biosciences | 10-Q: Quarterly report
Express News | Aura Biosciences Inc: Strong Cash Position Expected to Fund Operations Into Second Half of 2026
Aura Biosciences 1Q Loss/Shr 40c >AURA
Aura Biosciences 1Q Loss/Shr 40c >AURA
Press Release: Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoi
Raj Parekh to Exit Board at Aura Biosciences' Meeting